Hugo Geerts

Summary

Affiliation: In Silico Biosciences
Country: USA

Publications

  1. ncbi request reprint [The virtual synapse what is its contribution to understanding cholinergic neural transmission?]
    Hugo Geerts
    In Silico Biosciences, Inc, Philadelphie, USA
    Therapie 59:21-3. 2004
  2. ncbi request reprint Drug discovery in neurodegenerative diseases
    Hugo Geerts
    In Silico Biosciences, Center for Neurodegenerative Disease Research, Institute on Aging, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Sci Aging Knowledge Environ 2005:pe4. 2005
  3. ncbi request reprint Of mice and men: bridging the translational disconnect in CNS drug discovery
    Hugo Geerts
    In Silico Biosciences Inc, Berwyn, Pennsylvania 19312, USA
    CNS Drugs 23:915-26. 2009
  4. ncbi request reprint AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders
    Hugo Geerts
    In Silico Biosciences Inc, 686 Westwind Drive, Berwyn, PA 19104, USA
    Curr Opin Investig Drugs 9:800-11. 2008
  5. pmc A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences Berwyn, PA, USA Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA
    Front Pharmacol 4:47. 2013
  6. doi request reprint Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development
    Hugo Geerts
    In Silico Biosciences, Berwyn, PA, USA
    J Pharmacokinet Pharmacodyn 40:257-65. 2013
  7. pmc Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response
    Hugo Geerts
    In Silico Biosciences, Berwyn, Pennsylvania, United States of America
    PLoS ONE 7:e49732. 2012
  8. ncbi request reprint Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences Inc, 686 Westwind Drive, Berwyn, PA 19104, USA
    IDrugs 10:121-33. 2007
  9. ncbi request reprint Ispronicline (Targacept)
    Hugo Geerts
    In Silico Biosciences Inc, 3741 Walnut Street 609, Philadelphia, PA 19104, USA
    Curr Opin Investig Drugs 7:60-9. 2006
  10. doi request reprint α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences, Berwyn, USA
    Expert Opin Investig Drugs 21:59-65. 2012

Collaborators

Detail Information

Publications26

  1. ncbi request reprint [The virtual synapse what is its contribution to understanding cholinergic neural transmission?]
    Hugo Geerts
    In Silico Biosciences, Inc, Philadelphie, USA
    Therapie 59:21-3. 2004
    ..Validation of this system is performed by predicting the outcome in a preclinical setting and subsequent testing of this hypothesis. Some examples of this model with regard to the prediction of clinical outcome are presented...
  2. ncbi request reprint Drug discovery in neurodegenerative diseases
    Hugo Geerts
    In Silico Biosciences, Center for Neurodegenerative Disease Research, Institute on Aging, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Sci Aging Knowledge Environ 2005:pe4. 2005
    ..Some of the projects have resulted in very promising drugs, identified and developed by academic centers, entering clinical trials...
  3. ncbi request reprint Of mice and men: bridging the translational disconnect in CNS drug discovery
    Hugo Geerts
    In Silico Biosciences Inc, Berwyn, Pennsylvania 19312, USA
    CNS Drugs 23:915-26. 2009
    ..This includes the development of hybrid computational models, based upon documented preclinical physiology and pharmacology, but populated and validated with clinical data from actual patients...
  4. ncbi request reprint AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders
    Hugo Geerts
    In Silico Biosciences Inc, 686 Westwind Drive, Berwyn, PA 19104, USA
    Curr Opin Investig Drugs 9:800-11. 2008
    ..AL-208 is undergoing phase II clinical trials for the treatment of cognitive disorder and phase I clinical trials for ocular disease and cognitive deficits associated with coronary artery bypass graft or ischemia...
  5. pmc A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences Berwyn, PA, USA Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA
    Front Pharmacol 4:47. 2013
    ..We believe such an innovative approach when used carefully could change the Research and Development paradigm for symptomatic treatment in AD...
  6. doi request reprint Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development
    Hugo Geerts
    In Silico Biosciences, Berwyn, PA, USA
    J Pharmacokinet Pharmacodyn 40:257-65. 2013
    ..A powerful property is the ability to perform failure analysis. By giving examples from the CNS R&D field in schizophrenia and Alzheimer's disease, we will illustrate how this approach can make a difference for CNS R&D projects...
  7. pmc Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response
    Hugo Geerts
    In Silico Biosciences, Berwyn, Pennsylvania, United States of America
    PLoS ONE 7:e49732. 2012
    ....
  8. ncbi request reprint Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences Inc, 686 Westwind Drive, Berwyn, PA 19104, USA
    IDrugs 10:121-33. 2007
    ..The compound had also been under development for the treatment of prostate cancer; however, this indication was discontinued after disappointing phase IIa trial results...
  9. ncbi request reprint Ispronicline (Targacept)
    Hugo Geerts
    In Silico Biosciences Inc, 3741 Walnut Street 609, Philadelphia, PA 19104, USA
    Curr Opin Investig Drugs 7:60-9. 2006
    ..In July 2005, Targacept was preparing for a phase II study in patients with mild-to-moderate Alzheimer's disease...
  10. doi request reprint α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences, Berwyn, USA
    Expert Opin Investig Drugs 21:59-65. 2012
    ....
  11. ncbi request reprint Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease
    Hugo Geerts
    In Silico Biosciences Inc, Berwyn, PA 19312, USA
    J Clin Pharmacol 46:8S-16S. 2006
    ..The link between these systems suggests that AD therapies, which capitalize on this relationship, may be more effective in improving cognition than approaches focusing on a single system...
  12. ncbi request reprint Small steps towards treatment of incurable neurodegenerative diseases
    Hugo Geerts
    Drug Discovery in Neurodegenerative Disease symposium, 2 5 December 2004, Cold Spring Harbor Laboratory, NY, USA
    Drug Discov Today 10:391-3. 2005
  13. ncbi request reprint Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits
    Hugo Geerts
    In Silico Biosciences, Inc, 686 Westwind Drive, Berwyn, PA 19312, USA
    Brain Res 1033:186-93. 2005
    ..1 and 2.3 microg/g in rats, 8.3 and 0.65 microg/g for mice, and 19.1 and 1.3 microg/g in rabbits. The data also suggest that for a similar degree of brain AChE inhibition, 3-15 times higher galantamine than donepezil doses are needed...
  14. ncbi request reprint Indicators of neuroprotection with galantamine
    Hugo Geerts
    In Silico Biosciences, 686 Westwind Drive, Berwyn, PA 19312, USA
    Brain Res Bull 64:519-24. 2005
    ..These clinically relevant neuroprotective properties of galantamine are worthwhile exploring further and their clinical relevance may improve the development of new disease-modifying agents...
  15. ncbi request reprint NC-531 (Neurochem)
    Hugo Geerts
    In Silico Biosciences, 686 Westwind Drive, Berwyn, PA 19312, USA
    Curr Opin Investig Drugs 5:95-100. 2004
    ..Phase I clinical trials of NC-531 were ongoing in November 1999, and by October 2002 phase II trials were underway...
  16. ncbi request reprint Nicotinic cholinergic modulation: galantamine as a prototype
    Diana S Woodruff-Pak
    Albert Einstein Healthcare Network, Korman Suite 100, 5501 Old York Road, Philadelphia, PA 19141, USA
    CNS Drug Rev 8:405-26. 2002
    ....
  17. doi request reprint Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform
    Athan Spiros
    In Silico Biosciences, Inc, Berwyn, PA, USA
    J Parkinsons Dis 3:569-80. 2013
    ..Possible solutions for the low success rate in CNS Drug discovery and development in CNS diseases include drug repurposing...
  18. pmc Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
    Athan Spiros
    In Silico Biosciences, Berwyn, PA, USA
    Neuropsychiatr Dis Treat 6:589-603. 2010
    ..These results suggest that computer modeling of key CNS processes, using well-validated calibration paradigms, can increase the predictive value in the clinical setting of preclinical animal model outcomes...
  19. ncbi request reprint Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA
    J Alzheimers Dis 11:491-507. 2007
    ..The use of nAChR agonists and antagonists in some of these studies lends support to the proposed allosteric potentiating ligand activity of galantamine at nAChRs. This dual action of galantamine may account for its therapeutic profile...
  20. ncbi request reprint Neuroprotection and neurodegenerative diseases: from biology to clinical practice
    Yvette Akwa
    INSERM U488, Le Kremlin Bicetre, France
    Alzheimer Dis Assoc Disord 19:226-39. 2005
    ..Thus, elements of the response are beginning to be generated with a view to determining whether it will soon be possible to effectively slow or even stop the neurodegenerative process whose etiology, in most cases, remains obscure...
  21. ncbi request reprint [Pharmacology of Alzheimer's disease: where do we go from here?]
    François Sellal
    Hopital Universitaire, Strasbourg, France
    Therapie 60:89-107. 2005
    ..In conclusion, this prospective review should be considered as a guide in fostering drug innovation in Alzheimer's disease and related disorders and should help to decrease the gap existing between neuroscience and therapeutics...
  22. ncbi request reprint In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity
    Samir Kumar-Singh
    Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Born Bunge Foundation, University of Antwerp, B 2610 Antwerp, Belgium
    Neurobiol Dis 11:330-40. 2002
    ....
  23. ncbi request reprint Pharmacology of Alzheimer's disease: appraisal and prospects
    François Sellal
    Hopital Universitaire, Strasbourg, France
    Dement Geriatr Cogn Disord 19:229-45. 2005
    ..The implementation of considered strategies will require the involvement and close cooperation between political decisions, pharmaceutical companies and the scientific community...
  24. ncbi request reprint Neuropathobiology in transgenic mice. The case of Alzheimer's disease
    Jo Van Dorpe
    Experimental Genetics Group, Center for Human Genetics, Flemish Institute for Biotechnology, Katholieke Universiteit Leuven, Leuven, Belgium
    Methods Mol Biol 209:333-61. 2003